Telanodes

Operating subsidiaries built and run on the platform.

Telanodes are the asset entities Thelamux owns and capitalizes. Each one runs on the same THELA + MUX operating system from day one — and each Telanode makes the next one cheaper, faster, and more likely to succeed.

Telanode 01 · Active

Tethra Biosciences.

Tethra is developing plogosertib (THT-140) — a next-generation oral PLK1 + BRD4 inhibitor — for clinical-stage precision oncology and hematologic malignancies.

Acquisition to clinical readiness in under 10 months versus 18–36 months industry standard, with engagement from leading clinical sites and top KOLs across oncology and hematology.

Clinical-stage program

P1/2

Active in solid tumors

Global

Patent estate

Visit Tethra Biosciences →

Proof of model

Live validation that THELA + MUX produces clinical-stage assets.

Tethra is what the model looks like in practice — not a theoretical platform. The infrastructure built for Tethra is the same infrastructure the next Telanode will plug into.

Differentiated chemistry

A next-generation PLK1 inhibitor.

plogosertib is an oral small-molecule PLK1 inhibitor with an optimized profile for cancer indications — wholly owned by Tethra, protected by a global patent estate.

Disciplined development

Resource concentration.

A single chemistry advanced with clear go / no-go gates and resource concentration on the highest-conviction development paths.

Experienced operators

Oncology drug developers.

Regulatory leaders and clinical operators across hematology and solid tumors — running on the shared MUX infrastructure every future Telanode inherits.

Intellectual property

Global patent estate.

plogosertib is wholly owned by Tethra and protected by a global patent estate covering composition of matter and methods of use across major jurisdictions.

Regulatory

Standard FDA pathways.

Tethra is pursuing standard FDA development pathways for plogosertib across its indication tracks. Designations, trial registrations, and protocol details disclosed through official channels.

Structure

Platform-aligned ownership. Clinical-aligned operators.

Each Telanode is structured for platform alignment — Thelamux holds the controlling position while operators retain meaningful equity, and capital flows through THELA against pre-defined milestone gates.

The same template applied to Tethra scales to every future Telanode.

Operating principle

Centralized intelligence + execution.

THELA — strategic intelligence layer. Portfolio prioritization and capital allocation against milestone gates.

MUX — execution engine. Clinical operations, regulatory, CMC, and translational platform — built once, leveraged across every Telanode.

Pipeline of Telanodes

The platform is built to compound.

Tethra is Telanode #1. The next ones are already in motion — and each will plug into the same operating system on day one.

Telanode 01 · Active

Tethra Biosciences

Clinical-stage precision oncology developing plogosertib (THT-140) — a next-generation oral PLK1 inhibitor in active Phase 1/2.

Telanode 02

In sourcing

Active sourcing of the next clinical-stage asset under platform control. Targeting underutilized Phase 1/2 programs in oncology and rare disease.

Telanode 03+

Pipeline

Future Telanodes will plug into the same operating system — each one cheaper, faster, and structurally validated by the platform.